Will JBS trade at or above 6.0x EV/EBITDA (trailing) at any point in 2026?

JBS currently trades at roughly 4-5x EV/EBITDA based on $22.7B market cap and ~$6.8B EBITDA (plus net debt). Reaching 6.0x requires approximately a 20-30% expansion in EV/EBITDA, which is significant. The market would need to see either strong EBITDA growth reducing the denominator's effective date, or a meaningful EV expansion (stock price increase + net debt). Russell index inclusion (77% probability per our assessment) is the most concrete near-term catalyst, but the Myth Meter correctly notes that ESG-screened funds may limit passive inflows. The governance ceiling (85% Batista family control) creates a structural cap on multiple expansion.

The question asks about reaching 6.0x at ANY point in 2026, not sustaining it — this provides 9 months of opportunity. However, the required expansion is substantial. US protein peers trade at 6-8x EV/EBITDA, so 6.0x would still be at the low end of the peer range. The path requires: (1) Russell inclusion driving passive buying, (2) improving beef narrative, (3) continued analyst coverage expansion post-NYSE listing. Against this: the governance discount is likely permanent at 1-2x turns, meaning the 'fair' multiple considering governance may be 5-6x even as peer multiples are higher. The 6.0x target sits right at the boundary of where governance discount might cap the multiple.

The CFO noted that EV/EBITDA has 'traded higher than before listing but still at discount to peers.' Post-NYSE listing re-rating has already begun but stalled. The next catalysts — Russell inclusion, potential analyst initiations, and potential beef cycle improvement — could push the multiple toward 6.0x temporarily. However, the FY2025 EBITDA decline (-5%) means the denominator is also moving unfavorably. If EBITDA declines further in FY2026, reaching 6.0x would require an even larger stock price appreciation. The probability is pulled down by the dual headwinds of governance ceiling and potentially declining EBITDA.

The question asks if JBS reaches 6.0x at ANY point — not average or sustained. Market multiples fluctuate with daily stock price movements and trailing EBITDA calculations. A single strong quarter, positive analyst note, or Russell inclusion could temporarily push the multiple above 6.0x even if it doesn't sustain. The 'any point' criterion significantly increases the probability compared to a sustained 6.0x requirement. JBS's operational quality (25% ROE, 17% ROIC) and growing US investor base provide fundamental support for multiple expansion.

The Myth Meter's assessment of UNDERPRICED supports the case for multiple expansion, but the same lens noted that some discount is permanent given governance. The most likely path to 6.0x: Russell inclusion in June 2026 drives a short-term buying surge, temporarily pushing the multiple above 6.0x before settling back. This is the strongest near-term catalyst and has a ~77% probability of occurring. However, even with Russell inclusion, the buying may not be sufficient to move the multiple from ~4-5x to 6.0x given the company's large market cap ($22.7B).

US protein peers like Tyson Foods (TSN) trade at 7-8x EV/EBITDA. A re-rating to 6.0x would still leave JBS at a 15-25% discount to peers. As US investors gain familiarity with JBS post-NYSE listing, some convergence toward peer multiples is natural. The 9-month timeframe and 'any point' criterion provide sufficient opportunity for a combination of Russell inclusion, positive analyst coverage, and market sentiment to push the multiple to 6.0x temporarily. Probability is near the 40% level — meaningful chance but below coin-flip due to governance ceiling.

Current ~4-5x EV/EBITDA requires significant expansion to reach 6.0x. Russell inclusion is the primary catalyst but may not be sufficient to bridge the gap. Governance discount creates a ceiling. The 'any point' criterion helps but the gap is large.

Multiple expansion from ~4-5x to 6.0x requires either a 20%+ stock price increase with stable EBITDA or an EBITDA decline combined with even larger stock move. Both scenarios are unlikely in 2026 given the beef cycle drag and governance constraints. The operational quality is real but already partially reflected in the post-listing re-rating.

The combination of Russell inclusion (77% probability), growing US analyst coverage, and strong operational metrics creates a plausible path to temporary 6.0x. However, the governance discount and declining EBITDA trend work against sustained re-rating. Probability reflects the balance of catalysts vs. constraints over 9 months.